Frederic Pla - 07 Sep 2023 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Reporting relationship: Chief Operating Officer
Issuer ticker: AKYA
Reported as of: 07 Sep 2023
Net transaction value: +$92,014
SEC form: 4
Accepted by SEC: 11 Sep 2023, 16:00:06 UTC
Prior SEC filing: 27 Mar 2023
Next SEC filing: 27 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Frederic Pla, by Brian McKelligon, as Attorney-in-Fact

Key filing fact

Frederic Pla filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 11 Sep 2023.

Key facts

This page summarizes Frederic Pla's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 11 Sep 2023, 16:00.

Change

Previous filing in this sequence was filed on 27 Mar 2023.
Current net transaction value: +$92,014.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKYA transaction

Common Stock

Purchase

Transaction value: $59,814
Shares: +13,000
Change %
Price: $4.60
Shares after: 13,000
Date: 07 Sep 2023
Ownership: By The Pla Family Trust dtd 8/7/14
Footnotes: F1

AKYA transaction

Common Stock

Purchase

Transaction value: $32,200
Shares: +7,000
Change %: +54%
Price: $4.60
Shares after: 20,000
Date: 07 Sep 2023
Ownership: By The Pla Family Trust dtd 8/7/14

AKYA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 40,555
Date: 07 Sep 2023
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions with prices ranging from $4.595 to $4.61 for a weighted average sale price of $4.6011. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.